Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 5/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31046679 | 1.00 | NPC1 (0.50) | NPC1RAB9AMAOBIDO1AGXT | |
| SCHEMBL3510373 | 0.83 | IDO1 (0.43) | NPC1RAB9AMAOBIDO1AGXT | |
| SCHEMBL24869497 | 0.81 | KDM4E (0.51) | NPC1RAB9AMAOBIDO1AGXT | |
| SCHEMBL16332094 | 0.81 | APP (0.47) | NPC1RAB9AMAOBIDO1AGXT | |
| SCHEMBL30184138 | 0.81 | KDM4E (0.51) | NPC1RAB9AMAOBIDO1AGXT | |
| SCHEMBL1258945 | 0.80 | APP (0.59) | NPC1RAB9AMAOBIDO1AGXT | |
| SCHEMBL29007904 | 0.80 | ALOX5AP (0.49) | RAB9AMAOBIDO1AGXTMAPT | |
| SCHEMBL15205685 | 0.77 | MAOB (0.63) | NPC1RAB9AMAOBIDO1AGXT | |
| SCHEMBL10533393 | 0.77 | NPC1 (0.50) | NPC1RAB9AMAOBIDO1AGXT | |
| SCHEMBL31694526 | 0.77 | PDE2A (0.49) | NPC1RAB9AMAOBIDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2275414-B1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2275414-A1 | CYCLOPENTYLACRYLIC ACID AMIDE DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | NPC1 237/4885RAB9A 2029/4885MAOB 2578/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | NPC1 237/4885RAB9A 2029/4885MAOB 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.